Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30576999 | 1.00 | ALDH1A1 (0.77) | ALDH1A1HSD17B10TDP1KDM4EDYRK1A | |
| Ammonia Solution, Strong SCHEMBL28566017 | 0.98 | ALDH1A1 (0.74) | ALDH1A1HSD17B10TDP1KDM4EDYRK1A | |
| SCHEMBL16784221 | 0.94 | ALDH1A1 (0.69) | ALDH1A1HSD17B10TDP1KDM4EDYRK1A | |
| SCHEMBL30523585 | 0.94 | ALDH1A1 (0.69) | ALDH1A1HSD17B10TDP1KDM4EDYRK1A | |
| SCHEMBL1247490 | 0.94 | ALDH1A1 (0.69) | ALDH1A1HSD17B10TDP1KDM4EDYRK1A | |
| SCHEMBL14787821 | 0.94 | ALDH1A1 (0.69) | ALDH1A1HSD17B10TDP1KDM4EDYRK1A | |
| SCHEMBL14777332 | 0.94 | ALDH1A1 (0.69) | ALDH1A1HSD17B10TDP1KDM4EDYRK1A | |
| SCHEMBL14777264 | 0.94 | ALDH1A1 (0.69) | ALDH1A1HSD17B10TDP1KDM4EDYRK1A | |
| SCHEMBL16784222 | 0.94 | ALDH1A1 (0.69) | ALDH1A1HSD17B10TDP1KDM4EDYRK1A | |
| SCHEMBL3516862 | 0.92 | ALDH1A1 (0.71) | ALDH1A1HSD17B10TDP1KDM4EDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110467605-B | Preparation method of novel triarylpyrazoline derivatives and application of novel triarylpyrazoline derivatives in anticancer drugs | 南京大学 | 2022-07-29 | — | — | CN | claimed |
| CN-113005774-B | Preparation method and antibacterial application of thiosemicarbazone-Cu (II) complex molecule covalent grafting acrylic fiber | 武汉纺织大学 | 2022-03-18 | — | — | CN | claimed |
| CN-113735769-A | Quinolinone alkaloid derivative containing acylhydrazone structure at 3-position and preparation method and application thereof | 太原理工大学 | 2021-12-03 | — | — | CN | claimed |
| CN-113005774-A | Preparation method and antibacterial application of thiosemicarbazone-Cu (II) complex molecule covalent grafting acrylic fiber | 武汉纺织大学 | 2021-06-22 | — | — | CN | claimed |
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2021-06-10 | — | — | US | claimed |
| CN-108822072-B | Method for preparing Elligusurgitol | 中国医学科学院药物研究所 | 2021-01-12 | — | — | CN | claimed |
| US-20190322649-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2019-10-24 | — | — | US | claimed |
| CN-108822072-A | A method of preparing Yi Ligelusita | 中国医学科学院药物研究所 | 2018-11-16 | — | — | CN | claimed |
| US-20170334888-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2017-11-23 | — | — | US | claimed |
| CN-105801556-A | Preparation method of 2,3-dihydro-1,4-benzodioxane-6-carboxylic acid compound | 上海药谷药业有限公司 | 2016-07-27 | — | — | CN | claimed |
| EP-1075833-B1 | Barrier cream | SECR DEFENCE (GB) | 2005-04-13 | — | — | EP | claimed |
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | claimed |
| EP-1358169-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | claimed |
| WO-2002057261-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-25 | — | — | WO | claimed |
| US-6309631-B1 | OIL-BASED BASE CREAM, 40-50% W/W OF A 1:1 W/W MIXTURE OF TITANIUM DIOXIDE AND FERRIC OXIDE AND FROM 0 TO 20% W/W OF A MELT ADDITIVE; MITIGATION OF BURNS | SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 2001-10-30 | — | — | US | claimed |
| EP-1075833-A1 | Barrier cream | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2001-02-14 | — | — | EP | claimed |
| US-4582903-A | Synthesis of unsaturated hydantoins with an inexpensive catalyst | STAUFFER CHEMICAL COMPANY (US) | 1986-04-15 | — | — | US | claimed |
| EP-0031253-B1 | PROCESS FOR PREPARING 3,4-SUBSTITUTED BENZALDEHYDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-10-05 | — | — | EP | claimed |
| US-4345072-A | Process for the production of 5-arylidene hydantoins (B) | DEGUSSA AG (DE) | 1982-08-17 | — | — | US | claimed |
| EP-0031253-A1 | Process for preparing 3,4-substituted benzaldehydes | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-07-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | ALDH1A1 1857/4885HSD17B10 873/4885TDP1 3429/4885 |
| US-20170334888-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | ALDH1A1 1857/4885HSD17B10 873/4885TDP1 3429/4885 |
| US-20190322649-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | ALDH1A1 1857/4885HSD17B10 873/4885TDP1 3429/4885 |
| US-20040132807-A1 | Aurones as telomerase inhibitors | TERT, TERF2, TERF2IP | ALDH1A1 1344/4885HSD17B10 3179/4885TDP1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.